CD274 and esophageal squamous cell carcinoma: The benefit was particularly pronounced in patients with programmed death receptor ligand-1 (PD-L1) combined positive score (CPS) ≥ 10 in ESCC, where mOS was extended from 8.8 months to 13.9 months (7).